HELP Committee starts work to deliver lower pharmaceutical costs

By Ben Mouncer
A Senate committee has started to tackle the issue of pricing in the pharmaceutical industry. Earlier this week we reported a Managed Healthcare Execut...

A Senate committee has started to tackle the issue of pricing in the pharmaceutical industry.

Earlier this week we reported a Managed Healthcare Executive survey that highlighted costs as the biggest challenge facing the industry in the United States.

On Tuesday, the Health, Education, Labor and Pensions (HELP) Committee held the first of three hearings in Washington, D.C. to pool analysis and ideas from its range of experts.

Senators were warned that rocketing prices are leaving some medicines unaffordable for many people and that out-of-pocket expenses are rising.

Allan Coukell from Pew said a particular area of worry was specialty drugs, with high costs and further annual increases giving patients cause for concern.

Brands holding a monopoly on some drugs is also driving increases as Professor Gerard Andersen of Johns Hopkins University spoke of at the HELP Committee’s hearing.

"As any economist can tell you, when there’s a monopoly, they set the price that the market will bear," he said.

The next two hearings will focus on research & development and then supply chain expenses in the industry.

Work is also being done by Health and Human Services Secretary Tom Price to put together a plan to bring down the costs of pharmaceuticals.

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma